A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

28 Jan 2025 Planned primary completion date changed from 30 May 2025 to 1 Jun 2025.
10 Jan 2025 According to a Nektar Therapeutics media release, company is looking forward to announce the topline data from the 16week induction treatment period in this study in the second quarter of 2025.
10 Jan 2025 Status changed from recruiting to active, no longer recruiting according to a Nektar Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com